Velpatasvir

维帕他韦

Report date: 2025/06/26 20:00:07
NME

Base Information

Drug NameVelpatasvir
Drug Alias Name维他司韦VelpatasvirumGS-5816
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsRejection of lung transplantationDeglutition DisordersHepatitis C, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGilead Sciences IncUniversity Health Network (Uhn)
Inactive CompaniesRadboud University Medical CenterNational Institute Of Diabetes And Digestive And Kidney Diseases
Active IndicationsRejection of lung transplantationHepatitis C
Inactive IndicationsDeglutition DisordersHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG